NIH: Investigational ChAdOx1 nCoV-19 vaccine protects monkeys against #COVID19 pneumonia

We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. The presence of such antibodies has spurred hope that people exposed to SARS-CoV-2 may be protected, at least for a time, from getting COVID-19 again. But, in this post, I want to examine another potential use of antibodies: their promise for being developed as therapeutics for people who are sick with COVID-19.

In a recent paper in the journal Science, researchers used blood drawn from a COVID-19 survivor to identify a pair of previously unknown antibodies that specifically block SARS-CoV-2 from attaching to human cells [2]. Because each antibody locks onto a slightly different place on SARS-CoV-2, the vision is to use these antibodies in combination to block the virus from entering cells, thereby curbing COVID-19’s destructive spread throughout the lungs and other parts of the body. CLICK HERE.

0 views
  • LinkedIn - Black Circle
  • Facebook - Black Circle
  • Twitter - Black Circle

Find It Fast

Scimedico L.L.C.

T: 908.986.3000 

F: 480.275.3317

E: info@scimedico.com

Mailing:

623 Eagle Rock Avenue 

West Orange, NJ 07052

Headquarters:

210 Bellevue Avenue

Montclair, NJ 07043

© 2020 Scimedico, LLC